Major depressive disorder, chronic renal failure. Persistent mood [affective] disorders
Conditions
Interventions
Intervention 1: The intervention group: In this group escitalopram is prescribed .escitalopram dose increased from 5 mg to 10 mg per day. The drugs were selected from Tehran Pharmaceutical Company an
Sponsors
Yazd University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: Patients with major depressive disorder with minimum depression score of 13 with Hamilton Test and psychiatrist approval Patients with renal failure who have been undergoing hemodialysis treatment for at least 3 months
Exclusion criteria
Exclusion criteria: Systemic medical disease (heart disease, diabetes, epilepsy, hypertension, thyroid) that interferes with medication use or follow-up. Liver failure, Hepatitis B and C, HIV / AIDS Existence of psychiatric disorder other than depression Patient being treated with SSRIs (if previously treated after 3 months treatment) Pregnancy or lactation Addiction to all kinds of drugs and psychotropics The occurrence of any unbearable side effects in the patient
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Depression score on the Hamilton scale. Timepoint: Assessment of Hamilton depression score at baseline and 6 weeks after intervention. Method of measurement: Hamilton Depression Inventory. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side effect. Timepoint: At baseline (before intervention) and 6 weeks after drug administration. Method of measurement: Questionnaire designed by the researcher. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public Contactmina ayatollahi
Yazd University of Medical Sciences
Outcome results
None listed